Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
United States of America et al v. Janssen Pharmaceutical N.V. et al
Case Number:
2:16-cv-06997
Court:
Nature of Suit:
Judge:
Firms
Companies
Government Agencies
Sectors & Industries:
-
April 20, 2018
Janssen Escapes Whistleblower Suit Over Off-Label Opioids
A California federal judge Thursday nixed a False Claims Act suit accusing Johnson & Johnson subsidiary Janssen Pharmaceutical NV of using unlawful marketing practices to boost off-label sales of its opioid prescription drugs, saying a change of the pseudonym for the whistleblower who filed the suit violated the FCA's first-to-file doctrine.
-
March 20, 2018
Relator Assails Early Out For Janssen, J&J In Off-Label Row
A former Janssen Pharmaceutica NV sales representative who claims the drugmaker overcharged the government, offered kickbacks and marketed drugs off-label on Monday asked a California federal judge to keep the suit alive, rebuffing the company's arguments that she lacked corroboration and forfeited her right to sue by changing her alias.